Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 12, 2011, Pages 5703-5709

  Kim, Won Young ^a   Suh, Gee Young ^b   Huh, Jin Won ^a   Kim, Sung Han ^a   Kim, Min Ju ^a   Kim, Yun Seong ^c   Kim, Hye Ryoun ^d   Ryu, Yon Ju ^e   Han, Min Soo ^f   Ko, Young Gwan ^g   Chon, Gyu Rak ^h   Lee, Kwan Ho ⁱ   Choi, Sang Ho ^a   Hong, Sang Bum ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Pusan National University School of Medicine   (South Korea)

^d Korea Cancer Center Hospital   (South Korea)

^e Ewha Womans University School of Medicine   (South Korea)

^f Eulji University School of Medicine   (South Korea)

^g Kyung Hee University Hospital   (South Korea)

^h Konkuk University School of Medicine   (South Korea)

ⁱ Yeungnam University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; NEUROMUSCULAR BLOCKING AGENT; NITRIC OXIDE; OSELTAMIVIR; RIBAVIRIN; STEROID;

2009 H1N1 INFLUENZA; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; ARTICLE; ARTIFICIAL VENTILATION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATTRIBUTABLE RISK; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEMOLYTIC ANEMIA; HOSPITAL ADMISSION; HOSPITAL INFECTION; HUMAN; INFLUENZA VIRUS A H1N1; INTENSIVE CARE UNIT; KOREA; LIVER ENZYME BLOOD LEVEL; LIVER FAILURE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MULTICENTER STUDY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SEIZURE; SEPTIC SHOCK; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TRIPLE COMBINATION ANTIVIRAL DRUG THERAPY; VENTILATOR; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; AMANTADINE; ANTIVIRAL AGENTS; COHORT STUDIES; CRITICAL ILLNESS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; KOREA; MALE; MIDDLE AGED; OSELTAMIVIR; PANDEMICS; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME;

EID: 81555200483     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05529-11     Document Type: Article

References (42)

1. Abdel-Ghafar, A. N., et al. 2008. Update on avian influenza A (H5N1) virus infection in humans. N. Engl. J. Med. 358:261-273.
2. Ariano, R. E., et al. 2010. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 182:357-363.
3. Atkinson, W. L., et al. 1986. Amantadine prophylaxis during an institutional outbreak of type A (H1N1) influenza. Arch. Intern. Med. 146:1751-1756. (Pubitemid 16018916)
4. Bernard, G. R., et al. 1994. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am. J. Respir. Crit. Care Med. 149:818-824. (Pubitemid 24082248)
5. CDC. 2010. Interim recommendations for clinical use of influenza diagnostic tests during the 2009-10 influenza season. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/h1n1flu/guidance/ diagnostic-tests.htm.
6. CDC. 2009. 2008-2009 influenza season: week 36 ending September 12, 2009. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/ flu/weekly/weeklyarchives2008-2009/weekly36.htm.
7. Cohen, A., Y. Togo, R. Khakoo, R. Walderman, and M. Sigel. 1976. Comparative clinical and laboratory evaluation of the prophylactic capacity of ribavirin, amantadine hydrochloride, and placebo in induced human influenza type A. J. Infect. Dis. 133(Suppl.):A114-A120.
8. Dominguez-Cherit, G., et al. 2009. Critically ill patients with 2009 influenza A(H1N1) in Mexico. JAMA 302:1880-1887.
9. Dutkowski, R., et al. 2003. Safety and pharmacology of oseltamivir in clinical use. Drug Saf. 26:787-801. (Pubitemid 37056109)
10. Duval, X., et al. 2010. Efficay of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med. 7:e1000362.
11. Fiore, A. E., et al. 2011. Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 60:1-24.
12. Gaur, A. H., et al. 2010. Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. N. Engl. J. Med. 362:88-89.
13. Glaxo Wellcome, Inc. 2009. Relenza (zanimivir for inhalation) package insert. Glaxo Wellcome, Inc., Research Triangle Park, NC.
14. Hayden, F. G., et al. 1997. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N. Engl. J. Med. 337:874-880. (Pubitemid 27408569)
15. Hayden, F. G., C. A. Sable, J. D. Connor, and J. Lane. 1996. Intravenous ribavirin by constant infusion for serious influenza and parainfluenzavirus infection. Antivir. Ther. 1:51-56. (Pubitemid 126690049)
16. Hernandez, J. E., et al. 2011. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an emergency IND program in the United States. Clin. Infect. Dis. 52:695-706.
17. Ilyushina, N. A., E. Hoffmann, R. Salomon, R. G. Webster, and E. A. Govorkova. 2007. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir. Ther. 12:363-370. (Pubitemid 46787981)
18. Inoue, M., et al. 2010. Emergence of oseltamivir-resistant pandemic (H1N1) 2009 virus within 48 hours. Emerg. Infect. Dis. 16:1633-1636.
19. Ison, M. G., et al. 2003. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir. Ther. 8:183-190. (Pubitemid 36960891)
20. Kiatboonsri, S., C. Kiatboonsri, and P. Theerawit. 2010. Fatal respiratory events caused by zanamivir nebulization. Clin. Infect. Dis. 50:620.
21. Kidd, I. M., et al. 2009. H1N1 pneumonitis treated with intravenous zanamivir. Lancet 374:1036.
22. Knaus, W. A., E. A. Draper, D. P. Wagner, and J. E. Zimmerman. 1985. APACHE II: a severity of disease classification system. Crit. Care Med. 13:818-829. (Pubitemid 15250137)
23. Korean Society of Critical Care Medicine. 2010. KSCCM H1N1 registry. Korean Society of Critical Care Medicine, Seoul, Republic of Korea. http://www.ksccm.org.
24. Kumar, A., et al. 2009. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 302:1872-1879.
25. Magnussen, C. R., R. G. Douglas, Jr., R. F. Betts, F. K. Roth, and M. P. Meagher. 1977. Double-blind evaluation of oral ribavirin (Virazole) in experimental influenza A virus infection in volunteers. Antimicrob. Agents Chemother. 12:498-502. (Pubitemid 8192221)
26. McGeer, A., et al. 2007. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin. Infect. Dis. 45:1568-1575. (Pubitemid 351411840)
27. Memoli, M. J., et al. 2010. Rapid selection of a transmissible multidrug-resistant influenza A/H3N2 virus in an immunocompromised host. J. Infect. Dis. 201:1397-1403.
28. Moscona, A. 2008. Medical management of influenza infection. Annu. Rev. Med. 59:397-413. (Pubitemid 351287945)
29. Moscona, A. 2005. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 353:1363-1373. (Pubitemid 41362704)
30. Nguyen, J. T., et al. 2010. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 5:e9332.
31. Nicholson, K. G., et al. 2000. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 355:1845-1850. (Pubitemid 30311875)
32. Rello, J., et al. 2009. Intensive care adult patients with severe respiratory failure caused by influenza A (H1N1)v in Spain. Crit. Care 13:R148.
33. Shin, S. Y., et al. 2011. Drug-resistant pandemic (H1N1) 2009, South Korea. Emerg. Infect. Dis. 17:702-704.
34. Smee, D. F., B. L. Hurst, M. H. Wong, K. W. Bailey, and J. D. Morrey. 2009. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob. Agents Chemother. 53:2120-2128.
35. Snell, P., et al. 2005. Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate. Br. J. Clin. Pharmacol. 59:598-601. (Pubitemid 40632252)
36. Stein, D. S., et al. 1987. Oral ribavirin treatment of influenza A and B. Antimicrob. Agents Chemother. 31:1285-1287. (Pubitemid 17157618)
37. Takeda, M., A. Pekosz, K. Shuck, L. H. Pinto, and R. A. Lamb. 2002. Influenza A virus M2 ion channel activity is essential for efficient replication in tissue culture. J. Virol. 76:1391-1399. (Pubitemid 34070633)
38. Taylor, W. R., et al. 2008. Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. PLoS One 3:e3410.
39. van der Vries, E., F. F. Stelma, and C. A. Boucher. 2010. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N. Engl. J. Med. 363:1381-1382.
40. Vincent, J. L., et al. 1996. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 22:707-710.
41. World Health Organization. 2009. Antiviral use and the risk of drug resistance - pandemic (H1N1) 2009 briefing note 12. WHO, Geneva, Switzerland. http://who.int/csr/disease/swineflu/notes/h1n1-antiviral-use-20090925/en/index. html.
42. World Health Organization. 2009. Pandemic (H1N1) 2009 - update 65, September 11, 2009. WHO, Geneva, Switzerland. http://www.who.int/csr/don/2009- 09-11/en/index.html.